ArticleFrontiers in psychiatry2025
Transcriptomic analysis reveals the key role of inflammatory and immune signaling in the anti-perimenopausal depression effects of Bushen Shugan Huayu decoction.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Progress and challenges in exploring the pathogenesis of depressive disorders via RNA sequencing.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to explore the targets and signaling pathways significantly associated with perimenopausal depression through transcriptomics, as well as the potential intervention targets of the BSSGHY decoction. Methods: Five patients diagnosed with perimenopausal depression in Beijing were treated with the BSSGHY decoction and clinically observed. The severity of depression and associated symptoms was assessed using the HAMD, Kupperman, and PSQI scales before and after treatment, and serum levels of inflammatory factors were quantified using ELISA. Differentially expressed genes in PBMCs were identified through mRNA sequencing and subsequently analyzed using DESeq2 software. Statistical analyses were performed using GraphPad Prism 10.0, and GO and KEGG enrichment analyses were performed based on the hypergeometric distribution algorithm. Key differentially expressed genes were validated via RT-PCR (qPCR) to quantify mRNA expression levels. Results: Following BSSGHY decoction treatment, patients showed a significant reduction in HAMD scores (p < 0.01), marked symptom relief (p < 0.05), and decreased inflammatory factor levels (p < 0.01). We then conducted RNA-SEQ analysis before and after treatment in patients with perimenopausal depression. Inflammation-related genes such as CXCL8, IL1B, FOSL1, and OSM showed higher expression before treatment, with a downward trend afterward. The analysis of GO and KEGG pathways of differentially expressed genes showed that the involved biological processes and signaling pathways were closely related to inflammation and immunity. qRT-PCR validation showed that FOSL1 and OSM expression decreased after treatment (p < 0.05), while LINC01311 expression increased (p > 0.05). Conclusion: BSSGHY decoction effectively regulates inflammatory and immune factor signaling, reduces the body's inflammatory response, and improves perimenopausal depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.